Pharming Group NV (PHAR)
11.87
-0.03
(-0.25%)
USD |
NASDAQ |
Oct 27, 16:00
11.89
+0.02
(+0.17%)
After-Hours: 20:00
Pharming Group Enterprise Value : 808.61M for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 808.61M |
| October 26, 2026 | 810.73M |
| October 23, 2026 | 761.19M |
| October 22, 2026 | 723.67M |
| October 21, 2026 | 651.48M |
| October 20, 2026 | 658.56M |
| October 19, 2026 | 613.26M |
| October 16, 2026 | 630.96M |
| October 15, 2026 | 650.07M |
| October 14, 2026 | 650.77M |
| October 13, 2026 | 636.62M |
| October 12, 2026 | 648.65M |
| October 09, 2026 | 661.39M |
| October 08, 2026 | 642.99M |
| October 07, 2026 | 651.48M |
| October 06, 2026 | 653.60M |
| October 05, 2026 | 662.10M |
| October 02, 2026 | 658.56M |
| October 01, 2026 | 672.71M |
| September 30, 2026 | 675.55M |
| September 29, 2026 | 676.96M |
| September 28, 2026 | 713.06M |
| September 25, 2026 | 708.81M |
| September 24, 2026 | 707.40M |
| September 23, 2026 | 730.75M |
| Date | Value |
|---|---|
| September 22, 2026 | 765.43M |
| September 21, 2026 | 733.58M |
| September 18, 2026 | 715.18M |
| September 17, 2026 | 731.46M |
| September 16, 2026 | 718.72M |
| September 15, 2026 | 715.18M |
| September 14, 2026 | 734.29M |
| September 11, 2026 | 761.89M |
| September 10, 2026 | 733.23M |
| September 09, 2026 | 744.91M |
| September 08, 2026 | 782.42M |
| September 04, 2026 | 763.31M |
| September 03, 2026 | 779.59M |
| September 02, 2026 | 761.19M |
| September 01, 2026 | 754.82M |
| August 31, 2026 | 781.00M |
| August 28, 2026 | 796.58M |
| August 27, 2026 | 802.24M |
| August 26, 2026 | 814.27M |
| August 25, 2026 | 801.53M |
| August 24, 2026 | 779.59M |
| August 21, 2026 | 807.19M |
| August 20, 2026 | 795.16M |
| August 19, 2026 | 807.19M |
| August 18, 2026 | 811.44M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ProQR Therapeutics NV | 70.28M |
| NewAmsterdam Pharma Co. NV | 1.777B |
| argenx SE | 54.54B |
| Nektar Therapeutics | 747.50M |
| uniQure NV | 1.425B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.598M |
| Revenue (Quarterly) | 90.08M |
| Total Expenses (Quarterly) | 88.48M |
| EPS Diluted (Quarterly) | 0.02 |
| Gross Profit Margin (Quarterly) | 80.56% |
| Profit Margin (Quarterly) | 1.77% |
| Earnings Yield | 1.05% |
| Operating Earnings Yield | 2.56% |
| Normalized Earnings Yield | 1.877 |